Bryan Xiangrong Sim

Dr. Bryan Xiangrong Sim


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Ophthalmology Science
Verified
Journal Article
Open access
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
KLKai Lyn Loh
Kai Lyn Loh
HHHla Myint Htoon
Hla Myint Htoon
YSYudah Sri
Yudah Sri
MBMaithily Balakrishnan
Maithily Balakrishnan
ACAudrey Wei Lin Chia
Audrey Wei Lin Chia
Myopia progression in children, especially in East Asia, is a significant public health concern. This study evaluated the efficacy of combining myopia control spectacle lenses with Highly Aspherical Lenslet Target (HALT) technology and atropine in children who continued to progress on low-dose atropine (LDA). Prospective cohort. Children aged 6-11 years with ≥0.5 diopters (D) myopia progression over 6 months on LDA (0.01% or 0.025%) were recruited. All participants used HALT (Essilor Stellest) spectacle lenses while maintaining their LDA dose. The changes in spherical equivalent (SE) and axial length (AL) were tracked for 6 months before and 6-12 months after starting combination treatment. Progression of SE and AL. Fifty children (mean age 8.9 ± 1.1 years) were separated into group A (on 0.01% atropine daily, n20) and group B (on 0.01% atropine twice daily, n5 and 0.025% atropine nightly, n25). Most (86%) were ethnic Chinese. The baseline SE and AL showed no significant intergroup differences, with prior myopia progression (0.60D/0.24 mm) over 6 months. After adding HALT lenses, progression slowed to -0.06D/0.06 mm at 6 months and -0.15D/0.14 mm at 12 months. A hyperopic shift in AL was seen in 11 children (24%). However, the progression of >0.5D was noted in 20%, with 18% and 40% progressing by >0.3 mm and >0.15 mm, respectively. Univariate analysis suggested that children who progressed >0.10 mm over 6 months were more likely to be younger, whereas multivariate analysis suggested that change in AL was associated with smaller pupil size (possibly from poor compliance or absorption of atropine) at 6 months and younger age at 12 months, after controlling for sex, race, and baseline SE and AL. There were no complaints of glare, near, or peripheral blur in children after starting combination treatment. The addition of HALT spectacle lenses significantly reduced myopia progression in children, aged 6-11 years, who were poorly controlled on LDA alone demonstrating a potential synergistic effect with LDA. These findings supported combination therapy for managing challenging myopia cases. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

23 November 2024 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
RCRachel Chong
Rachel Chong
HHHla Myint Htoon
Hla Myint Htoon
MBMaithily Balakrishnan
Maithily Balakrishnan
NBNoel A. Brennan
Noel A. Brennan
ACAudrey Wei Lin Chia
Audrey Wei Lin Chia
This study aimed to investigate the longitudinal associations between myopic optic disc features and optical coherence tomography (OCT) measurements of peripapillary retinal nerve fibre layer (RNFL) thickness in young myopic children in Singapore. A prospective, single-site cohort study was conducted, involving children aged 7 to 16 years who participated in the PROM-Kids clinical cohort study from 2019 to 2022. Participants underwent annual assessments, including cycloplegic refraction, axial length measurements, fundus photography, and OCT imaging, with ocular magnification correction. Children were classified into low (LM, 0 to -3D), moderate (MM, -3.01 to -6D), and high (HM, > -6D) myopia, with or without treatment. Data from 1,000 children (right eye) were analyzed, including 521 with 2-year follow-up. At baseline, the mean age was 10.2 ± 1.6 years, with 46.4% male and 90.7% ethnic Chinese. HM children were older and exhibited greater optic disc tilt (ODT, 92% vs. 80%) and more peripapillary atrophy (PPA, 94% vs. 73%) compared to LM children. RNFL thickness decreased in the superior, inferior, and nasal quadrants but increased in the temporal quadrant with higher myopia. In the follow-up cohort, myopia progression was associated with thicker temporal quadrant and average RNFL, particularly in younger children. Prior treatment with myopia-control lenses was also associated with increased RNFL thickness in the superior quadrant. Optic disc changes occur early in life, even in low myopia. Increasing myopia is linked to varying RNFL thickness across quadrants and may be influenced by age and myopia treatment.

4 November 2023 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Closed access
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
JNJanice Wan Zhen Ng
Janice Wan Zhen Ng
DSDonald Yuhui Sim
Donald Yuhui Sim
JGJeannette Goh
Jeannette Goh
SKSylvia Kam
Sylvia Kam
SJSaumya Shekhar Jamuar
Saumya Shekhar Jamuar


19 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
KLKai-lyn Loh
Kai-lyn Loh
PCPauline Poh Lin Chan
Pauline Poh Lin Chan
SYSri Yudah
Sri Yudah
ACAudrey Wei Lin Chia
Audrey Wei Lin Chia
Objectives: To evaluate the 24-month efficacy of combining highly aspherical lenslet target (HALT) spectacle lenses with low-dose atropine (LDA) in children with poor response to atropine monotherapy. Methods: This prospective interventional cohort study included myopic children aged 6–11 years who continued to progress despite LDA (0.01–0.025%). Fifty children completed 12 months of follow-up and 48 completed 24 months. At 12 months, atropine dosage was maintained, reduced, or increased according to clinical discretion. Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline, 12 months, and 24 months. Results: Myopia progression during the first year (SER: −0.07 ± 0.45 D; AL: 0.13 ± 0.14 mm) was markedly lower than during the 6 months before treatment (SER: −0.61 ± 0.39 D; AL: 0.24 ± 0.12 mm). During the second year, atropine dosage was reduced in 23%, maintained in 67%, and increased in 10% of participants. Mean second-year progression was −0.26 ± 0.41 D and 0.17 ± 0.17 mm, with no significant differences between treatment groups. Although second-year SER progression exceeded first-year progression (p = 0.003), both SER and AL progression remained significantly lower than pre-treatment rates (p = 0.004). Over 24 months, 73.9% of eyes progressed ≤ 0.50 D and 71.7% progressed ≤ 0.40 mm. Younger age and greater first-year progression independently predicted greater 24-month SER and AL progression. Conclusions: Myopia progression was relatively well sustained over 24 months after combination treatment was started in children previously progressing on LDA. Younger children and those with greater early progression may warrant closer monitoring.

4 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NKNg Kaiwen
Ng Kaiwen
AGAaron Qi Yang Goh
Aaron Qi Yang Goh
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
SYSri Yudah
Sri Yudah
PCPauline Poh Lin Chan
Pauline Poh Lin Chan
ACAudrey Wei Lin Chia
Audrey Wei Lin Chia
Aim: In this retrospective audit, Atropine 0.025% eyedrops were evaluated in a clinical setting. Method: Children aged 4–16 years, who were started on Atropine 0.025% with at least 6 months of follow-up, were included. A total of 588 eyes (299 children) were classified as treatment-naïve eyes started on Atropine 0.025% daily (Group A, n146), eyes progressing on Atropine 0.01% daily increased to 0.025% daily (Group B, n287) or combined with myopia control glasses (Group C, n66), and those stable on Atropine 0.01% twice daily converted to Atropine 0.025% daily (Group D, n89). Spherical equivalent (SE) and axial length (AL) were recorded from 6 months before treatment to 24 months after treatment began. Result: Group A children were younger (8.4 ± 1.5 years), while Group D children were older (10.6 ± 1.59 years). Progression in the first 6 m was significantly less than that in 6 m prior in Groups A-C. At 1 year, a change in AL < 0.15 mm was noted in 41%, 49%, 50% and 35%, and a change in AL ≥ 0.30 mm was observed in 38%, 18%, 32% and 23% of eyes in Groups A, B, C and D, respectively. Treatment was increased in 37%, 34%, 12% and 41% of eyes over 2 years in Groups A, B, C and D, respectively. Mean progression at 2 years was −0.63 ± 0.86 D or 0.44 ± 0.31 mm, −0.39 ± 0.59 D or 0.30 ± 0.26 mm, −0.30 ± 0.48 D or 0.36 ± 0.40 mm, and −0.48 ± 0.54 D or 0.33 ± 0.22 mm in Groups A, B, C and D, respectively. Multivariate analysis suggested that progression was mainly associated with younger age. Conclusions: Atropine 0.025% was a useful addition to myopia control, with some eyes requiring further modification in treatment.